keep some cash, keep good stocks based on own risk level and cash:stock ratio.
make sure we can sleep well, not influenced by stock volatility.

will slowly go beyond RM15, why?

because many retailers went to vaccine counter and technology counters.
because foreign funds and big funds still here. retailers only remain 10-15% in glove counters.
no more contra players because burnt heavily.
because no safe and effective vaccine.
because covid-19 cases still increasing.

@Stockisnotfun , you continue to stay in Holland. No need to come back first.

Guys, @Stockisnotfun already at Holland now, pity him.

Stockisnotfun I will be waiting u all at another side of Holland
02/09/2020 5:01 PM

Yes, you @Tigerwoods is correct.

Bonus issue of up to 5,476,974,322 new ordinary shares in Top Glove Corporation Bhd ("Top Glove") ("Bonus Shares") on the basis of two (2) Bonus Shares for one (1) existing ordinary share held in Top Glove as at 5.00 p.m. on 4 September 2020 ("Entitlement Date").

Those laugh and see bad on glove because they have vaccine counters. But what happen to Vaccine counters today? Limit up?
Short cut to use vaccine emergency, let's see what are the effect and whether they need more glove or not. By Nov, you will know Vaccine is more worth or glove is more worth. No need to argue, two more months you will see the outcome.

bonus share will only in your account on 7-Sep after 5pm

Sorry, i also think 0.50 is really impossible. 1.25 can or not? 1.25 I want to buy some, if drop to 1.20 add on again.

Wait for 0.50 or below, then i want to buy

while glove counters not moving, why vaccine counters also cannot move?
any vaccine counter expert want to share?

Pang72, have you ALL IN?

Read the positive on vaccine enough. The negative info may be fake. Don't believe negative comments. We need to selectively choosing what we believe only.


Sinovac's coronavirus vaccine candidate approved for emergency use in China — source
Roxanne Liu
/
Reuters

August 29, 2020 19:54 pm +08


State media Xinhua reported late on Friday that two vaccine candidates were approved in June for the emergency use program launched in July, without identifying the specific products.

Officially, China has given little details on which vaccine candidates have been given to high-risk people under the emergency use programme and how many people have been vaccinated.

In June, prior to the emergency use programme, employees at state firms travelling overseas were allowed to take one of the two vaccines being developed by CNBG, state media Global Times reported. China's military had also approved the use of CanSino Biologics' vaccine candidate.

Seven vaccines against the coronavirus are in final trial stages around the world, and four of them are from China.

But no vaccine has yet passed the final stage of trials proving it is safe and effective — conditions usually required to be met to get regulatory approval for mass use. Covid-19 has killed over 800,000 people worldwide.

I don't have pharma but i know many supporters are here. so i cannot talk bad about vaccine, not good to talk bad. So i choose to support you all. Please buy as many as possible if you trust all vaccine companies.

Don't miss the boat. The boat is about to start sailing. Time to sailang before it start sailing.

Pang, don't under estimate pharma. 6.00? next week 8.00, will be fierce like glove counters. by end of Sep, it will go above 15.00. ALL IN


pang72 Pharma easily over Rm6 next week
29/08/2020 9:41 PM

Read carefully

THE CEO OF THE SAID INVENTOR OF THE VACCINE WILL STAND UP AND SHOW THAT IS THE DOOR IN AND THE DOOR OUT,

PERHAPS, NOT HE MAY IN HIS SITTING POSITION, NOT SO GRACIOUS,
WITH HAND POINTING TO THE OUT/
DOOR SIGNAGE.

Anyone heard about bonus issue?


SEE_Research Boustead

Pls read carefully, this is current report by the
Edge Markets,
Reporting time :20:28,
11August 2020

On the current situation by Boustead, Malaysia on the
Court actions on totally
5 previous Board of Directors (including the previous MD) for
BREACHING THEIR FIDUCIARY OBLIGATIONS AS DIRECTORS UNDER COMPANIES ACT 1965
SUM INVOLVED RM 35.37 millions


=======================================
Remarks
(i) sum involved is RM 35.37millions and not small amount
(ii) AND NOT OLD REPORT thru WhatsApp, etc
(iii) To be honest, some of my close investors have interest to invest in the pharmaceutical stocks, and upon ongoing researches manage to find the skeletons in the closet.

Sincerely,

When some of the investors in this forum requested for further information,
the necessary replies as per their request.
Likely, when the management of some rubber gloves stocks run into some
BAD malpractices,
the necessary reports will be issued, too.

Top rated: RM25 within 18 months. Trust Khairy kao kao


All hands on deck to re-purpose existing plants for Covid-19 vaccine, says Pharmaniaga
Author: savemalaysia | Publish date: Sun, 23 Aug 2020, 11:30 AM


KUALA LUMPUR, Aug 23 — Pharmaniaga Bhd says it is all geared up to make the necessary changes to its existing plants that would enable them to undertake fill and finish process for Covid-19 vaccine as soon as it is developed, its acting managing director, Mohamed Iqbal Abdul Rahman said.


He said the group had presented to the National Science Council its plan, capacity and capabilities for the purpose.


“This is part of the short-term plan of the group in addressing the urgent need for the Covid-19 vaccine,” he told Bernama in a written reply when asked on Pharmaniaga’s future plans.


Last month, Science, Technology and Innovation Minister Khairy Jamaluddin said the government had agreed that the facilities owned by Duopharma Biotech Bhd and Pharmaniaga be used for bottling the vaccine.


Khairy reportedly explained that the two companies were chosen as both are government-linked — Duopharma is owned by Permodalan Nasional Bhd and Pharmaniaga is owned by Boustead Holdings Bhd — and currently have unused capacity that can be directed towards this purpose.


Going forward, Mohamed Iqbal said Pharmaniaga, Malaysia’s largest pharmaceutical company, was on track to establish the world’s first halal vaccine facility, targeted for completion by 2022.


“In 2018, Pharmaniaga announced plans to establish a vaccine plant. We have since completed conducting the necessary due diligence and secured partnerships with international vaccine producers,” he said.


In addition, Pharmaniaga has long-term plans for sustainable growth and has put in place six strategic thrusts to drive the company to the next level.


As a government-linked company, Pharmaniaga is committed to continuously provide the highest standard of service to allow the Ministry of Health to focus on healthcare delivery, with Pharmaniaga as its preferred logistics partner.


“Although we have secured a logistics and distribution contract until November 2024, we are hopeful that our proven track record, ready infrastructure, integrated information technology, and most importantly, experienced human capital, will position us well to secure a potential extension following this period,” he said.


Mohammed Iqbal said Pharmaniaga also benefitted significantly from the group’s digitalisation efforts which have taken place over the past few years, ensuring minimal disruptions during the Movement Control Order (MCO) period.


In an effort to augment the group, he said Pharmaniaga will also be expanding its product portfolio with new products to be manufactured in-house, as well as strengthen its agency and distributorship segment and expand its one-stop centre facilitation.


“With over 300 alliances and more than 6,000 private hospitals, general practitioners and pharmacy outlets, Pharmaniaga has a very strong base to build on and further strengthen customer loyalty,” he added.


Additionally, in an effort to strengthen human capital, the group will continue to equip its employees with the necessary training and support to comply with all regulatory and statutory requirements.


“With a workforce of more than 3,500, our human capital is our most valuable asset. We are also committed to prioritising local employment, with a workforce comprising 99.5 per cent locals, supported by specialised international talent mainly in our research and development team.


“We are also adapting to the ‘new normal’ post- Covid-19 and harnessing positive learnings from the MCO. Online meetings and work from home have given us the opportunity to ‘do more for less’ as we have less travelling cost and more productive time,” he added.


For the six-month financial period ended June 30, 2020, Pharmaniaga recorded a net profit of RM32.38 million as compared with RM28.89 million year-on-year (y-o-y), while revenue jumped to RM1.47 billion versus RM1.39 billion registered in the same period in 2019.


He said despite recording revenue growth y-o-y, the group’s Indonesian operations have been loss-making over the years, although there has been some slight improvement.


During the second quarter of 2020 especially, the Indonesia division recorded a deficit of RM2 million, mainly due to higher finance costs as a result of the delay in payments from government hospitals, currently affecting Indonesia’s healthcare industry.


“The division was further impacted by the republic’s large-scale social restrictions in response to the Covid-19 pandemic, which resulted in limited access to doctors, clinics, pharmacies and hospitals,” it said in a filing to Bursa Malaysia.


Mohamed Iqbal said to mitigate this, the company is seeking solutions to manage the delays in payment by government hospitals for the distribution business.

As for the manufacturing facility in Bandung, Pharmaniaga

Pharma will go beyond RM20 by next year with this business, 2m invested. Buy now or regret.
Next week limit up.


We are positive on Pharmaniaga’s ability to take part in the Covid-19 vaccine fill and finish process. We feel that it has the capacity, capabilities and expertise. We keep our forecasts unchanged at this juncture, and will revisit when more clarity is given on the Covid-19 vaccines bottling process.


With more plans unveiled on its “vaccine foray”, coupled with strong sentiment on such plays, we raise our PE target from 18x (+1SD to 5 year mean) to 21.5x (+2SD). This raises our TP from RM4.95 to RM5.94. BUY rating maintained. Our TP is de rived from P/E target of 21.5x (+2SD above 5 year mean) pegged to mid FY21 EPS.


We attended Pharmaniaga’s briefing and the following are some key takeaways:


World’s first halal vaccine facility. Pharmaniaga’s journey to have the world’s first halal vaccine facility started back in 2018. It has visited and established partnership with vaccine producers from China, India, Russia and Thailand.


It aims to trade 12 general vaccines, and already have 1 product registered. The first floor of their Puchong plant will be made to cater for the vaccine facility (12 general vaccines; 5 fill and finish process and 6 trading vaccines) is expected to be ready in 2022.


3 phases of execution. Pharmaniaga is focused on going into the above in 3 phases. Firstly, it will venture into this via registration and trading; registering the vaccine would approximately takes 2 years and then only it can be traded. Secondly, fill and finish in new prefilled syringes lines (RM100m investment), of which the vaccine will be put into individual syringes instead of in a bottle, and product development of new vaccines.


For the latter, we understand that a new patented vaccine is projected to be ready in 2024. Lastly, a new vaccine manufacturing plant (RM100m investment) is expected to be ready in 2026.

Covid-19 vaccine fill and finish. In Malaysia, there are not many companies with the capabilities to do a “fill and finish” process. To have a facility and getting it to be up and running would take about 3 years. The registration process itself would take about 2 years to obtain.


Pharmaniaga’s Small Volume Injectable (SVI) plant is suitable for Covid-19 fill and finish for inactivated/killed vaccine. This facility is a sterile GMP approved plant and the only SVI plant in Malaysia with EU GMP. For Pharmaniaga, the plan is that when the government has gotten a vaccine, Pharmaniaga would repurpose its ground floor plant located in Puchong to be able to do the fill and finish process; this plant has the required capacity and capabilities. While some changes are needed to be done (i.e. additional attachment equipment), it will roughly cost less than RM2m, and the period to implement the changes is fast (c.1 month).


Current projected capacity from this is 10m doses per month on 10 doses vial (1 bottle having 10 doses). Pharmaniaga is of the opinion that the earliest bottling process for Covid19 vaccine would be in 1Q21. While the government has yet to announce the participation of Pharmaniaga in Covid-19 vaccine, we are positive that Pharmaniaga will be the ideal choice, having all the capabilities intact.


Looking ahead. Pharmaniaga intends to increase its presence in the private sector by increasing its product range, especially in the over-the-counter segment. To remain competitive, Pharmaniaga is looking into therapeutics, vaccines, and insulins.


Forecast. We keep our forecasts at this juncture, as the fill and finish process will not start immediately and there are still multiple things that needs to be panned out first, most importantly, an actual discovery of the vaccine.



Maintain BUY, TP: RM5.94. With more plans unveiled on its “vaccine foray”, coupled with strong sentiment on such plays, we raise our PE target from 18x (+1SD to 5 year mean) to 21.5x (+2SD). This raises our TP from RM4.95 to RM5.94. We maintain BUY. Our TP is derived from P/E target of 21.5x (+2SD above 5 year mean) pegged to mid FY21 EPS.


Source: Hong Leong Investment Bank Research - 25 Aug 2020

Good news! Please read!

（吉隆坡24日讯）发马（PHARMA,7081,主板医疗保健组）只需投资200万令吉便可运用现有设施进行冠病疫苗灌封，每月将可灌封1000万剂量的疫苗。

代董事经理莫哈末依克巴指出，集团已向全国科学理事会提呈计划、产能与能力详情。

“一旦有疫苗，便可开始灌封，以解决国内对冠病疫苗的紧急需求。目前挑战是全球抢订疫苗，对发马而言有了疫苗便可即时灌封。”

科学、工艺与革新部长凯里上月指出，政府同意让发马与联合药业（DPHARMA,7148,主板医疗保健组）成为疫苗灌封中心。

莫哈末依克巴指出，该家国内最大药业公司，将于2022年完成设立清真疫苗中心。

该家政府相关公司制定6大策略带领公司至另一层次，将持续提供最高水平服务，让卫生部履行保健义务，发马则是最佳物流伙伴。

“虽然获取分销与物流订单至2024年，但我们也期许良好纪录、原有基建、整合资讯工艺，最重要的是经验丰富人力资源，可获考量延长有关订单。”

他说，这些年来发马已开展数码措施，确保行管期间受干扰程度减至最低。公司将扩大产品组合，新产品由内部生产，将强化代理与经销渠道和扩展一站中心等。

“发马有300策略伙伴，超过6000家私人医院、全科医生、药剂行等，同时将进一步加强消费者忠诚度。”

发马继续给予现有员工所需培训，遵守法规与法定需求。

目前该公司聘3500员工，这是其最重要资产，其中国内员工占99.5%，国际人才多在研发部。

他表示，发马已采纳新常态营运方式，除居家工作和线上会议，体现更大效益。

截至今年6月30日上半年，净利从前期2889万令吉增长至3238万令吉，营收从13亿9000万增加至14亿7000万令吉。

次季印尼业务仍然蒙亏200万令吉，主要是高融资成本和政府医院延迟付款；正采取措施客服此问题。预期万隆生产设施扩展销售渠道，2021年有望盈亏持平，印尼业务长远有望转亏为盈。



https://www.sinchew.com.my/content/content_2331320.html

KUALA LUMPUR (Aug 25): theedgemarkets.com highlighted 11 stocks at Bursa Malaysia’s afternoon close today. One stock displayed positive momentum while 10 showed negative momentum.

The stock with positive momentum was:

M3 Technologies Asia Bhd — up 1.5 sen at 16.5 sen

Sponsored Content

Stocks with negative momentum were:

B.I.G. Industries Bhd — up four sen at 57 sen

Bintai Kinden Corp Bhd — up 25.5 sen at 66 sen

Duopharma Biotech Bhd — up 71 sen at RM4.09

Grand-Flo Bhd — up 3.5 sen at 31 sen

Ho Wah Genting Bhd — up 12 sen at RM1.23

LebTech Bhd — up one sen at RM1.22

Pharmaniaga Bhd — up RM1.11 at RM6.38

Rev Asia Bhd — up 3.5 sen at 29 sen

Solution Group Bhd — up 18 sen at 81 sen

WMG Holdings Bhd — up 2.5 sen at 16 sen

The list of stocks with momentum is generated using a proprietary mathematical algorithm highlighting stocks with a build-up in trading volume and price. The algorithm differentiates between stocks that exhibit positive (+ve) momentum and negative (-ve) momentum.

This list is not a buy or sell recommendation. It merely tells you which stocks are seeing higher than normal volume and price movements.

The share price may move up or down from this point. But the “+ve” (suggesting a rising price trend on volume) and “-ve” (suggesting a falling price trend on volume) indicators should give readers a better idea of what the market is buying and when to sell. Note also that momentum generally only persists for a short period of time.

However, each stock has an accompanying fundamental score and valuation score to help readers evaluate the attractiveness of the stocks, if they want to ride the momentum.

Edited by Lam Jian Wyn

Solution should invest 2m and work with vaccine companies, then Solution can be another pharma

So awesome profit, i also want to buy pharma.
but why not kyy invest 2m instead?

Caring pharmacy also can invest 2m for the business right?

Monday, 25 March 2013
Caring Pharmacy Group Berhad & Pharmacy Industry in Malaysia
In 2012, there were 2,095 community pharmacies in Malaysia.



As at 31 December 2012, Caring has a total number of 76 community pharmacies operating under the name of 'CARiNG". For FYE 31 May 2012, Caring achieved revenue of RM248.28m, or on average RM3.27m/ pharmacy.

RM[x]m, representing approximately 41.15% of the gross proceeds will be utilised towards expansion of new community pharmacy outlets, setting up 25 to 30 new community pharmacies in Peninsula Malaysia.

Major suppliers (supplies more than 10% of total products offering)
Zuellig Pharma Sdn Bhd
DKSH Malaysia Sdn Bhd




Average revenue per type of outlet

Shopping complex: RM3.86m/outlet
Street outlet: RMRM2.89m/outlet
Specialised retail centre: RM2.35m/outlet












Capital and Set-up Costs
The barriers to entry into the community pharmacy industry are relatively low based on capital requirements (excluding land and building)

The capital requirements of setting-up an independent community pharmacy would be between RM200,000 to RM400,000 which includes both renovation costs (

IJM should also invest 2m, then can go back to MSCI

If 2m to get 2b revenue or profit, then this is really a great business to go for.
But why only pharma?

@SE_Research, does it means pharma just spend 2 millions for this business and plan to make 2 billions revenue or profit?

Pharmaniaga ready to back govt in Covid-19 vaccine supply
GROOVE
'Black Panther' star Chadwick Boseman dies from colon cancer
Pharmaniaga ready to back govt in Covid-19 vaccine supply
WORLD
Riot in Sweden amidst Quran-burning rally
Pharmaniaga ready to back govt in Covid-19 vaccine supply
NATION
Ally Mukhriz 'deeply ashamed' for breaking RMCO rules
Pharmaniaga ready to back govt in Covid-19 vaccine supply
NATION
RMCO extended until Dec 31, says PM Muhyiddin
Pharmaniaga ready to back govt in Covid-19 vaccine supply
NATION
Poor Sabah farmer wins RM19.88 million Sports Toto jackpot


BUSINESS
Pharmaniaga ready to back govt in Covid-19 vaccine supply
Ayisy Yusof
By Ayisy Yusof
August 24, 2020 @ 6:48pm

Pharmaniaga ready to back govt in Covid-19 vaccine supply
Pharmaniaga acting managing director Mohamed Iqbal Abdul Rahman said the G2G arrangements would be vital for Malaysia to procure the vaccine but currently the details had yet to be ironed out.
KUALA LUMPUR: Pharmaniaga Bhd is ready to support the government in supplying Covid-19 vaccine locally, which is expected to be commercially available as early as the first quarter (Q1) of 2021

However, the supply will be heavily dependent on the government-to-government (G2G) arrangements in procuring the vaccine from the potential producing countries (China and India).


Market observers said the Covid-19 vaccine was slated to be readily available by end of this year.

The vaccine was reportedly in various clinical trials in high-case countries such as China, India, the United States and Russia.

Pharmaniaga acting managing director Mohamed Iqbal Abdul Rahman said the G2G arrangements would be vital for Malaysia to procure the vaccine but currently the details had yet to be ironed out.

"We have the existing capability and infrastructure to repurpose our vaccine plant to facilitate the 'fill and finish' for the vaccine if the government secures the procurement from producers," he said at Pharmaniaga's second quarter result briefing today.

Mohamed Iqbal said Pharmaniaga was ready in terms of logistics and distribution.

"We will allocate about RM2 million investment to repurpose our existing small volume injectable plant. This is to cater for the Covid-19 fill and finish for the inactivated/killed vaccine.

@SE_Research, what does this message means?

When the Malaysian interested companies approach the
Principal vaccine originator ,
in their initial discussion, when ask to state their keeness to participate in the refilling, repacking, storage and final deliveries,
HOW MUCH WILL BE YOUR INITIAL CAPITAL INVESTMENTS, WHEN OUR REPLY IS AROUND
USD 476,000.00,
THE CEO OF THE SAID INVENTOR OF THE VACCINE WILL STAND UP AND SHOW THAT IS THE DOOR IN AND THE DOOR OUT,

PERHAPS, NOT HE MAY IN HIS SITTING POSITION, NOT SO GRACIOUS,
WITH HAND POINTING TO THE OUT/
DOOR SIGNAGE.


====================================
REMARKS

THE REPACKING, REFILLING PROCESSES ARE I NOT,
IS NOT THAT SIMPLE,
LIKE REFILLING BOTTLED DRINKS,
PLASTICS BOTTLES POUR INTO,
IT IS CAPITAL INTENSIVE PROCESSES WITH VALUED ADD,
COMPLETE
IN THE TOTAL LOGISTICS WITH THE OPTIMUM COLD ROOM TEMPERATURE FACILITIES

can get enough fridge?


This chapter provides best practice guidance for storage
and handling. Additional resources are available in
Appendix C.
Vaccine Storage and Handling
There are few immunization issues more important than
the appropriate storage and handling of vaccines. The
success of efforts against vaccine-preventable diseases
is attributable in part to proper storage and handling of
vaccines. Vaccines exposed to temperatures outside the
recommended ranges can have reduced potency and
protection. Storage and handling errors can cost thousands
of dollars in wasted vaccine and revaccination. Errors can
also result in the loss of patient confidence when repeat
doses are required. It is better to not vaccinate than to
administer a dose of vaccine that has been mishandled.
Vaccine management, including proper storage and
handling procedures, is the basis on which good immuniza
-
tion practices are built.
Vaccines must be stored properly from the time they
are manufactured until they are administered. Proper
maintenance of vaccines during transport is known as the
cold chain. A proper cold chain is a temperature-controlled
supply chain that includes all equipment and procedures
used in the transport and storage and handling of vaccines
from the time of manufacturer to administration of the
vaccine. By following a few simple steps and implementing
best storage and handling practices, providers can ensure
that patients will get the full benefit of vaccines they
receive.
Vaccine Storage Temperatures
Vaccines are fragile. They must be maintained at the
temperatures recommended by vaccine manufacturers
and protected from light at every link in the cold chain.
Most live virus vaccines tolerate freezing temperatures, but
deteriorate rapidly after they are removed from storage.
Inactivated vaccines can be damaged by exposure to
temperature fluctuations (e.g., extreme heat or freezing
temperatures). Potency can be adversely affected if
vaccines are left out too long or exposed to multiple
temperature excursions (out-of-range temperatures) that
can have a cumulative negative effect. It is a good idea to
post a sign on the front of the storage unit(s) indicating
which vaccines should be stored in the freezer and which
should be stored in the refrigerator.

KUALA LUMPUR (Aug 11): Boustead Holdings Bhd confirmed that it has filed a suit at the High Court against its former managing director Tan Sri Che Lodin Wok Kamaruddin and five former directors, seeking £6.4 million (RM35.37 million).

However, the diversified conglomerate, which is controlled by Lembaga Tabung Angkatan Tentera with a 59.42% stake, pointed out that the writ is yet to be served.

"The writ is yet to be served," it said. "Announcement on the development of the above matter will be made in due course."

Boustead also confirmed that the claim is "up to £6.4 million or other sum deemed fit by the court, for breaching their fiduciary obligations as directors under the Companies Act 1965".

Referring to an article by theedgemarkets.com, Boustead said the writ "has indeed been filed on June 29, 2020" against the six individuals.

Apart from Lodin, others are former chairman Tan Sri Mohd Ghazali Che Mat, as well as former directors Datuk Azzat Kamaludin, Datuk Francis Tan Leh Kiah, Datuk Seri Ghazali Mohd Ali and Datuk Wira Dr Megat Abdul Rahman Megat Ahmad.

Lodin resigned in November 2018, while Mohd Ghazali retired as Boustead chairman in July last year. The other four directors, too, left the group last year.

Boustead had been subject to criticism due to high debt strain from its expansion exercises.

It resulted in a total borrowing of RM7.9 billion against shareholders' equity of RM3.74 billion at end of last year.

Amid high debt and shrinking cash flow as its businesses underperformed, Boustead was in the red in the financial year ended Dec 31, 2018 (FY18) and in FY19, when it opted for a RM1.15 billion kitchen-sinking to tidy its books.

It is currently said to be undertaking a debt restructuring of RM5.4 billion plus the rationalisation of non-core assets to improve cash flow.

wow, lengthy sharing from @SEE_Research.
good, please share lengthy lengthy messages. Please continue to spam pharma and dpharma rooms.

let's leave haters here to syiok sendiri

glove top fans, don't waste time over here. bring the fans the right place.

i want to buy Mi. Greatec and UWC already up. Previously they up one by one. Now Mi is leftover. I want to buy some next week to keep.

long time not visit here. so that's my comment for now.
I will not say good or bad about glove or vaccine anymore. I will just hold cash to wait.
If vaccine is good, then i will rather going into other recovery sector instead of vaccine because i strongly believe vaccine company profit will not be significant and will not last long like glove.

There are many sectors in KLSE if vaccine works.

nothing will be there forever. glove will end one day but doesn't mean vaccine company will be super star like glove had.

Vaccine believers, please don't be sad because i know you all sold glove counters and made a lot too. Now all in to vaccine companies but still seeing glove counters price cannot drop and still going up. Don't be sad. This is life and this is mankind. We tends to make mistake. God will bless you from making mistake but will not bless you if you keep talking bad about others without strong justification to support.

Let's talk about logic instead of innocent speak.

Vaccine companies in Malaysia will not be able to make profit like glove companies who sell to worldwide. Malaysia vaccine companies will only sell to Malaysian. How much they can make?

Many companies in many countries also aim to bottle, produce, value-added, and etc on vaccine. Do you think they will allow companies in Malaysia to produce, value-added, bottling, etc for their country? Do you think their companies in their countries unable to facilitate this services for their people?

Our vaccine companies can sell to worldwide after value added process? Forward PE can go so high like glove companies? Stock price can x4, x5 and etc? QR profit will x3, x4 or x5?

If you really think so, then i would suggest you can all in to all vaccine companies immediately before too late.

When i saw someone said pharma can go to RM15, i really want to laugh until cry.

But if you don't have glove companies, and keep saying bad about glove companies in glove room, obviously you need pushes from glove retailers to help pushing in vaccine companies. We know glove companies are really gone case, finish, end , can bankrupt, but this is what we do not believe, like you all still believe pharma stock price can go beyond 15, 20, 30 with PE of 80, 100,150.

You go believe yours in your vaccine room and celebrate with your vaccine believers, not here. We do believe our glove companies, at least for now because no one can know what will happen in future. You go believe your vaccine companies, not here.

Goreng and invest is different thing.

If vaccine come out, you will also not able to make loss from vaccine companies. End up vaccine kills more people because too rush for production. Then glove will shines even brighter.



@gemfinder Glove wil sufer bigest drop when trump aprove vacine in oct
29/08/2020 9:52 AM

@Gooner82 https://edition.cnn.com/world/live-news/coronavirus-pandemic-08-28-20-...

Check this out guys. India has surpasses previous record on daily high. Might need to shift the gloves supply to India for the next 3 months. In reality, glove counter is one of the few Malaysian companies that will thrive and showing great return to shareholders for the next 12 months.

They are the Pride of Malaysian right now in Bursa!
29/08/2020 8:58 AM

Tomorrow limit up or not?

ALL IN?

jacky9599 still can enter?
28/08/2020 1:03 PM

www.bursamalaysia.can-buy-gets_or-not.com

i think and think and think, don't know why

If like this buy Bursa better. Sure profit if every buy and sell so frequent

history repeat even though you know the trick. That's why majority keep losing money

sharks flush all out and pushing up again?? So retailers go in again?

@CUTLOST, you are a very bad guy. See what you said? 9 minutes can change so fast. You want to exit and say good news so that people conned by you??????


CUTLOST Bye bye Gets..
28/08/2020 12:24 PM

CUTLOST Gd news coming soon..
28/08/2020 12:15 PM

rebound from 0.245. sure many see good now?

@jupiter, please check in this link
www.bursamalaysia.can-buy-gets_or-not.com


jupiter can buy now?
28/08/2020 12:18 PM

not good to say bad things also because people already decided and they know the risk.
let's shout together, limit up, limit up, limit up

great news is coming, not only good. i help you all to scream.
people love to buy, we cannot stop. no good to stop people to buy.

K1 cannot go already. K1 result so bad. Once result out is bad, no one wants.
Gets no result yet, can buy, see people want share don't want money